[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"undefined\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:undefined":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":45},"100491192","phase-2-a-study-of-photobiomodulation-pbm-therapy-in-people-with-oral-graft-versus-host-disease-gvhd-after-stem-cell-transplant-100491192",false,"NCT05675930","A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant","A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)","Inclusion Criteria:\n\n* Allo-HCT recipients\n* Age ≥ 4 years-old\n* Oral cGvHD with NIH-modified OMRS score ≥ 3 who have failed ≥ 1 line of therapy, including topical corticosteroids..\n* No change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollment.\n* If a patient is currently using another oral topical treatment for mouth lesions\u002Fsymptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. Patient may continue same topical dose\u002Ffrequency during the study period.\n\nExclusion Criteria:\n\n* Presence of an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible.\n* Personal history of mucosal head and neck cancer in the past 5 years.\n* Pregnant or breastfeeding.\n* The subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.\n* Any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.","ALL","4 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to find out whether photobiomodulation\u002FPBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease\u002FGVHD.",[26,27,28],"Graft-Versus-Host Disease","GVHD","Undefined",[26,27,30,31,32,33],"Chronic Graft Versus Host Disease Oral","PhotobiomoduLatIon","Memorial Sloan Kettering Cancer Center","22-271","RECRUITING","2026-05-20",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":38},"2022-12-22",{"date":42,"type":20},"2026-12-22",{"name":32,"class":44},"OTHER",9,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100577179","study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment-100577179","NCT06794931","Study on the Impact of a Modified Mediterranean Diet, in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment","Randomized Pilot Study on the Impact of a Modified Mediterranean Diet (DMM) on the Intestinal Microbiota and Clinical Outcome in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment","MIC-1","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status (ECOG): 0 or 1;\n* Age ≥ 18;\n* Diagnosis of metastatic colorectal cancer, documented histologically and radiologically according to RECIST 1:1 criteria;\n* 1st line chemotherapy treatment +\u002F- biological agent (anti-EGFR, anti-VEGF);\n* MUST score 0\u002F1;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Previous oncological medical therapies;\n* Indication for parenteral and\u002For enteral nutrition;\n* MUST score \\> 2.","18 Years","80 Years",{"count":57,"type":20},40,[59],"NA","The study plans to evaluate the impact of the Modified Mediterranean Diet on the biodiversity of the intestinal microbiota (the set of physiological bacteria present at the intestinal level) in patients suffering from metastatic colorectal cancer undergoing chemotherapy treatment +\u002F- biological agent, comparing the microbiota with that of patients following a Western or standard diet.\n\nSpecifically, as well demonstrated in clinical studies, there are populations of bacteria that play a role in protecting the intestinal barrier and whose proliferation could be promoted by the Modified Mediterranean Diet.\n\nThe study also intends to evaluate the influence of the microbiome on the clinical progress of the disease in terms of side effects and quality of life.",[28],[63,64,65],"Colorectal Cancer Metastatic","modified Mediterranean diet","Intestinal microbiota","2025-01-24",{"date":68,"type":38},"2025-01-27",{"date":70,"type":38},"2024-07-24",{"date":72,"type":20},"2028-07-23",{"name":74,"class":44},"Azienda Socio Sanitaria della Brianza",1]